Covid-19 Vaccine: Wits trial results published in New England Journal
The complete analysis of the trial indicates that there may be a modest protective effect of prior exposure to the original Covid-19 strain.
New England Journal of Medicine (NEJM).
Wits University announced in a statement on Thursday that the NEJM, recognised as the world’s leading medical journal, had published the findings of the Phase 2b clinical trial conducted at Wits University in South Africa. The article was published on 5 May.
Shabir Madhi, Professor of Vaccinology, co-author of the study, and the Director of the Vaccines & Infectious Diseases Analytics Research Unit (Wits VIDA), led the Novavax Covid-19 vaccine trial in SA.
5 May 2021 - Wits University
Results from the initial primary analysis of the Novavax Covid-19 vaccine trial conducted by Wits VIDA in SA have been published.
The
New England Journal of Medicine (NEJM) today published findings of the Phase 2b clinical trial conducted in South Africa.
NEJM is recognised as the world’s leading medical journal.
Shabir Madhi, Professor of Vaccinology, co-author of the study, and the Director of the Vaccines & Infectious Diseases Analytics Research Unit (Wits VIDA), led the Novavax Covid-19 vaccine trial in South Africa.
The published data provide additional detail of an initial analysis conducted in January, while more robust data from a complete analysis of the study was subsequently shared in March 2021.
5 May 2021 - Wits University
Results from the initial primary analysis of the Novavax Covid-19 vaccine trial conducted by Wits VIDA in SA have been published.
The
New England Journal of Medicine (NEJM) today published findings of the Phase 2b clinical trial conducted in South Africa.
NEJM is recognised as the world’s leading medical journal.
Shabir Madhi, Professor of Vaccinology, co-author of the study, and the Director of the Vaccines & Infectious Diseases Analytics Research Unit (Wits VIDA), led the Novavax Covid-19 vaccine trial in South Africa.
The published data provide additional detail of an initial analysis conducted in January, while more robust data from a complete analysis of the study was subsequently shared in March 2021.